Fusion Antibodies plc
FAB.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 73% | -60.8% | -39.5% | – |
| Gross Profit | £0 | -£0 | £0 | £0 |
| % Margin | 21.9% | -23.3% | 7% | 35.8% |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -82.6% | -181.8% | -85.6% | -11.9% |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -87.2% | -196% | -89.5% | -25% |
| EPS Diluted | -0.018 | -0.04 | -0.1 | -0.046 |
| % Growth | 55.4% | 59.8% | -115.6% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |